Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome.
Hematopoietic stem cell transplantation (HSCT) is the only curative therapy for patients with myelodysplastic syndrome (MDS). However, the morbidity and mortality associated with conventional HSCT have traditionally prevented many patients from undergoing such treatment. Recent advances, including better prognostic algorithms, the introduction of reduced intensity conditioning regimens, and experience with alternative donors, have made HSCT a realistic option for an increasing number of patients with MDS.
Bone Marrow Transplant Program, Massachusetts General Hospital 55 Fruit Street, Boston, MA 02114 USA.
Yi-Bin
YB
Chen
Karen K
KK
Ballen